Rohto Pharmaceutical Co Ltd
TSE:4527
Rohto Pharmaceutical Co Ltd
EPS (Diluted)
Rohto Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rohto Pharmaceutical Co Ltd
TSE:4527
|
EPS (Diluted)
¥129
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Shiseido Co Ltd
TSE:4911
|
EPS (Diluted)
-¥27
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kao Corp
TSE:4452
|
EPS (Diluted)
¥231
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
4%
|
|
|
Kose Corp
TSE:4922
|
EPS (Diluted)
¥131
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-5%
|
|
|
F
|
Fancl Corp
TSE:4921
|
EPS (Diluted)
¥58
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
12%
|
|
|
Kobayashi Pharmaceutical Co Ltd
TSE:4967
|
EPS (Diluted)
¥135
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-1%
|
|
Rohto Pharmaceutical Co Ltd
Glance View
Rohto Pharmaceutical Co Ltd., a company deeply rooted in the legacy of Japanese innovation, traces its beginnings to the late 19th century. Initially specializing in over-the-counter (OTC) medicines, it has adeptly expanded its reach to include skincare and healthcare products. The company’s journey from its inception was marked by a relentless pursuit of addressing the evolving needs of its consumer base, leveraging its expertise in pharmaceuticals and chemistry to create products that cater to health and wellness. Rohto's commitment to research and development has enabled it to pioneer unique formulations, effectively blending traditional practices with modern scientific advances. This strategy has allowed Rohto to establish a strong foothold not only in Japan but also in international markets, appealing to a broad demographic. The core of Rohto's business lies in its ability to commercialize its innovative solutions across various channels. The company generates revenue primarily through the sale of its diversified product lines, which include eye drops, dermatological creams, and other personal care products. Rohto’s strategic acquisitions and partnerships have also played a critical role in its growth, enabling it to expand its market presence and adapt to global health trends. The ability to anticipate and respond to consumer needs allows Rohto to maintain a robust product pipeline, ensuring consistent sales performance. Through its global distribution networks and focused marketing efforts, Rohto capitalizes on its brand reputation for quality and reliability, ensuring a steady stream of profits.
See Also
What is Rohto Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
129.3
JPY
Based on the financial report for Dec 31, 2024, Rohto Pharmaceutical Co Ltd's EPS (Diluted) amounts to 129.3 JPY.
What is Rohto Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
8%
Over the last year, the EPS (Diluted) growth was -4%. The average annual EPS (Diluted) growth rates for Rohto Pharmaceutical Co Ltd have been 9% over the past three years , 5% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet